Search
Dipivefrin
go.drugbank.com/drugs/DB00449ApprovedWithdrawnIt is available as ophthalmic solution (eye drops).
Pyridoxal phosphate
go.drugbank.com/drugs/DB00114ApprovedInvestigationalNutraceuticalThis is the active form of vitamin B6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid.
Albiglutide
go.drugbank.com/drugs/DB09043ApprovedInvestigationalWithdrawnAlbiglutide was approved on April 15, 2014 by the FDA.
Digoxin
go.drugbank.com/drugs/DB00390ApprovedInvestigational[A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. … They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.[A178240]
Lenacapavir
go.drugbank.com/drugs/DB15673ApprovedInvestigational[L42995] On December 22, 2022, it was also approved by the FDA.[L44473] … [A244170, A244175, A244180, A244190] Lenacapavir was first globally approved on August 22, 2022 by the European Commission to treat adults with multi-drug resistant HIV infection.
Simoctocog alfa
go.drugbank.com/drugs/DB09108ApprovedAs patients with haemophilia A are predisposed to episodes of recurrent bleeding [L1115], simoctocog alfa can be administered for the treatment or prevention of bleeding such as prior to surgical procedures … It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system.
Suzetrigine
go.drugbank.com/drugs/DB18927ApprovedInvestigational[A264953] On January 30, 2025, suzetrigine was approved by the FDA as a first-in-class non-opioid analgesic.[L52098]
Belatacept
go.drugbank.com/drugs/DB06681ApprovedInvestigationalThe drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. … It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011.
Delandistrogene moxeparvovec
go.drugbank.com/drugs/DB16802ApprovedInvestigationalIt was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).